Linked Life Data

18020621

Source:http://linkedlifedata.com/resource/pubmed/id/18020621

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2007-11-20
pubmed:abstractText
Normal human somatic cells undergo telomeric attrition causing replicative senescence. Most immortal cancer cells cope with this by upregulating the active form of telomerase. Long-term inhibition of telomerase results in telomeric attrition and highly specific killing of cancer cells, in which the maintenance of telomere length is reliant on telomerase activity. Unfortunately, telomere erosion requires many cell divisions, possibly opening the way for acquired drug resistance. Recent attempts to solve this problem include the development of drugs that are more potent catalytic inhibitors, deny telomerase access to the telomere in situ, or affect telomere structure; some of these drugs have entered clinical trials. Combinations of these approaches may ultimately produce the best clinical results. This article reviews the latest results in both basic and applied telomere research that indicate the most promising avenues for future anticancer drug development in this area.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1173-8804
pubmed:author
pubmed:issnType
Print
pubmed:volume
21
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
375-85
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Anticancer therapy targeting telomeres and telomerase : current status.
pubmed:affiliation
Queen Mary's School of Medicine and Dentistry, Centre for Clinical and Diagnostic Oral Sciences, Institute of Cell and Molecular Sciences, London, England. e.k.parkinson@qmul.ac.uk
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't